In 1983, AIDS was diagnosed for the first time in two patients in South Africa. The first recorded AIDS-related death occurred in the same year. The project was dogged by controversy and was finally shelved in 1996. From 6 to 10 March 1995, the 7th International Conference for People Living with HIV and AIDS was held in
Cape Town, South Africa. The conference was opened by then-Deputy President
Thabo Mbeki. In January 1996, it was decided that South Africa's national soccer team,
Bafana Bafana, would contribute to the AIDS Awareness Campaign by wearing red ribbons to all their public appearances during the
Africa Nations Cup. On 5 July 1996, South Africa's Health Minister,
Nkosazana Dlamini-Zuma, spoke at the 11th
International Conference on AIDS in
Vancouver. She said: In February 1997, the South African government's Health Department defended its support for the controversial AIDS drug
Virodene by stating that "the 'cocktails' that are available [for the treatment of HIV/AIDS] are way beyond the means of most patients [even from developed countries]". Parliament had previously launched an investigation into the procedural soundness of the clinical trials for the drug. In 1999, the South African HIV prevention campaign
LoveLife was founded.
2000s In 2000, the Department of Health outlined a five-year plan to combat AIDS, HIV, and STIs. A National AIDS Council (SANAC) was set up to oversee these developments. The South African government successfully defended against a legal action brought by
transnational pharmaceutical companies in April 2001, challenging a law that would allow the importation of cheaper, locally produced medicines, including
anti-retrovirals. However, the government's rollout of anti-retrovirals remained generally slow. Also in 2001,
Right to Care, an NGO dedicated to the prevention and treatment of HIV and associated diseases, was founded. Using
USAID's
PEPFAR funding, the organisation expanded rapidly and after ten years (2011) had over 125,000 HIV-positive patients in clinical care. In 2002, South Africa's
Constitutional Court ordered the government to remove restrictions on the drug
nevirapine and make it available to pregnant women in all state hospitals and clinics to help
prevent mother-to-child transmission of HIV, following a court challenge by
Treatment Action Campaign and others. In 2007,
Anand Reddi and colleagues at the
PEPFAR funded Sinikithemba HIV/AIDS clinic at
McCord Zulu Hospital in
KwaZulu-Natal,
South Africa published the first report demonstrating paediatric antiretroviral therapy can be effective despite the challenges of a resource-limited setting. Notably, the model at Sinikithemba HIV/AIDS clinic demonstrated the benefits of a family centred model of care and data suggests that an HIV-positive primary caregiver was found to be protective against
paediatric mortality.
2020s In 2025, President of the United States,
Donald Trump, cut foreign aid funding to numerous countries, directly impacting a major HIV research project in South Africa In July 2025, South Africa secured R520 million (approximately USD 29 million) in funding from the Global Fund to Fight AIDS, TB, and Malaria. The funding will be used to purchase the biannual anti-HIV injection,
lenacapavir, manufactured by
Gilead Sciences. Research has shown that lenacapavir, an
antiretroviral medication, could work towards ending HIV/AIDS in South Africa. == Demographics ==